Literature DB >> 16333314

Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

Alessio Di Fonzo1, Cristina Tassorelli, Michele De Mari, Hsin F Chien, Joaquim Ferreira, Christan F Rohé, Giulio Riboldazzi, Angelo Antonini, Gianni Albani, Alessandro Mauro, Roberto Marconi, Giovanni Abbruzzese, Leonardo Lopiano, Emiliana Fincati, Marco Guidi, Paolo Marini, Fabrizio Stocchi, Marco Onofrj, Vincenzo Toni, Michele Tinazzi, Giovanni Fabbrini, Paolo Lamberti, Nicola Vanacore, Giuseppe Meco, Petra Leitner, Ryan J Uitti, Zbigniew K Wszolek, Thomas Gasser, Erik J Simons, Guido J Breedveld, Stefano Goldwurm, Gianni Pezzoli, Cristina Sampaio, Egberto Barbosa, Emilia Martignoni, Ben A Oostra, Vincenzo Bonifati.   

Abstract

Mutations in the gene leucine-rich repeat kinase 2 (LRRK2) have been recently identified in families with Parkinson's disease (PD). However, the prevalence and nature of LRRK2 mutations, the polymorphism content of the gene, and the associated phenotypes remain poorly understood. We performed a comprehensive study of this gene in a large sample of families with Parkinson's disease compatible with autosomal dominant inheritance (ADPD). The full-length open reading frame and splice sites of the LRRK2 gene (51 exons) were studied by genomic sequencing in 60 probands with ADPD (83% Italian). Pathogenic mutations were identified in six probands (10%): the heterozygous p.G2019S mutation in four (6.6%), and the heterozygous p.R1441C mutation in two (3.4%) probands. A further proband carried the heterozygous p.I1371 V mutation, for which a pathogenic role could not be established with certainty. In total, 13 novel disease-unrelated variants and three intronic changes of uncertain significance were also characterized. The phenotype associated with LRRK2 pathogenic mutations is the one of typical PD, but with a broad range of onset ages (mean 55.2, range 38-68 years) and, in some cases, slow disease progression. On the basis of the comprehensive study in a large sample, we conclude that pathogenic LRRK2 mutations are frequent in ADPD, and they cluster in the C-terminal half of the encoded protein. These data have implications both for understanding the molecular mechanisms of PD, and for directing the genetic screening in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16333314     DOI: 10.1038/sj.ejhg.5201539

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  50 in total

1.  Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.

Authors:  Ignacio F Mata; Greggory J Wilhoite; Dora Yearout; Justin A Bacon; Mario Cornejo-Olivas; Pilar Mazzetti; Victoria Marca; Olimpio Ortega; Oscar Acosta; Carlos Cosentino; Luis Torres; Angel C Medina; Carolina Perez-Pastene; Fernando Díaz-Grez; Carles Vilariño-Güell; Pablo Venegas; Marcelo Miranda; Osvaldo Trujillo-Godoy; Luis Layson; Rodrigo Avello; Elena Dieguez; Victor Raggio; Federico Micheli; Claudia Perandones; Victoria Alvarez; Juan Segura-Aguilar; Matthew J Farrer; Cyrus P Zabetian; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2011-05-31       Impact factor: 4.891

2.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan.

Authors:  Alessio Di Fonzo; Yah-Huei Wu-Chou; Chin-Song Lu; Marina van Doeselaar; Erik J Simons; Christan F Rohé; Hsiu-Chen Chang; Rou-Shayn Chen; Yi-Hsin Weng; Nicola Vanacore; Guido J Breedveld; Ben A Oostra; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2006-04-22       Impact factor: 2.660

Review 3.  The pleomorphic pathology of inherited Parkinson's disease: lessons from LRRK2.

Authors:  Vincenzo Bonifati
Journal:  Curr Neurol Neurosci Rep       Date:  2006-09       Impact factor: 5.081

4.  The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence.

Authors:  E K Tan; Y Zhao; L Skipper; M G Tan; A Di Fonzo; L Sun; S Fook-Chong; S Tang; E Chua; Y Yuen; L Tan; R Pavanni; M C Wong; P Kolatkar; C S Lu; V Bonifati; J J Liu
Journal:  Hum Genet       Date:  2006-09-30       Impact factor: 4.132

5.  Medical management of Parkinson's disease.

Authors:  Marvin M Goldenberg
Journal:  P T       Date:  2008-10

6.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Adriana Cardozo; Maria Jesus Rey; Eduardo Tolosa
Journal:  BMJ Case Rep       Date:  2009-01-23

7.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Authors:  Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2011-08-30       Impact factor: 44.182

8.  Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila.

Authors:  Dario C Angeles; Patrick Ho; Ling Ling Chua; Cheng Wang; Yan Wann Yap; Cheehoe Ng; Zhi dong Zhou; Kah-Leong Lim; Zbigniew K Wszolek; Hong Y Wang; Eng King Tan
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

Review 9.  The genetics of Parkinson's disease: progress and therapeutic implications.

Authors:  Andrew B Singleton; Matthew J Farrer; Vincenzo Bonifati
Journal:  Mov Disord       Date:  2013-01       Impact factor: 10.338

10.  Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease.

Authors:  Corinne Lautier; Stefano Goldwurm; Alexandra Dürr; Barbara Giovannone; William G Tsiaras; Gianni Pezzoli; Alexis Brice; Robert J Smith
Journal:  Am J Hum Genet       Date:  2008-03-20       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.